Clinical Ophthalmology Dovepress

hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms retinal vascular occlusion: a window to diagnosis of familial and acquired thrombophilia and hypofibrinolysis, with important ramifications for pregnancy outcomes Aim: Our specific aim was to document the pathoetiologic importance of thrombophilia among females presenting with severe ischemic retinal vein (RVO) or retinal artery (RAO) occlusion, without typical risk factors, and to emphasize that the ophthalmologists' diagnosis of throm-bophilia has important diagnostic and therapeutic downstream ramifications for nonocular thrombosis, including reproductive outcomes. Methods: We evaluated familial and acquired thrombophilia in 60 females with RVO (central RVO, n=52; branch RVO, n=8) and 16 with RAO (central RAO, n=11; branch RAO, n=5). They were referred by retinologists, without typical risk factors for RVO/RAO and/or severe ocular ischemic presentation. We focused on extraocular thrombotic events, particularly pregnancy complications, including unexplained spontaneous abortion, pre-eclampsia–eclampsia. Thrombophilia measurements in the 76 females were compared with 62 healthy normal females without ocular vascular occlusions (OVOs). Results: The 76 females with OVO were more likely than 62 normal female controls to have (22%) had 2 spontaneous abortions and/or pre-eclampsia–eclampsia. Compared to 62 healthy female controls, these 17 females with pregnancy complications had high homocysteine (29% vs 0%, P=0.0003), high anticardiolipin antibody immunoglobulin M (24% vs 3%, P=0.02), high factor VIII (38% vs 11%, P=0.02), and were marginally more likely to be heterozygous for the factor V Leiden mutation (19% vs 3%, P=0.058). Conclusion: In females lacking typical risk factors for retinal vascular occlusion or severely ischemic presentation, by diagnosing thrombophilia as an etiology for OVO, the ophthalmologist opens a window to family screening and preventive therapy, with particular relevance to pregnancy outcomes and venous thromboembolism.

[1]  I. Greer,et al.  Thrombophilia and Pregnancy Complications , 2015, International journal of molecular sciences.

[2]  D. Chang,et al.  A prospective 3-year follow-up trial of implantation of two trabecular microbypass stents in open-angle glaucoma , 2015, Clinical ophthalmology.

[3]  E. Steegers,et al.  Associations between phenotypes of preeclampsia and thrombophilia. , 2015, European journal of obstetrics, gynecology, and reproductive biology.

[4]  P. Christos,et al.  Risk Factors and Treatment Strategies in Patients With Retinal Vascular Occlusions , 2015, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[5]  A. Keshtkar,et al.  Evaluation of Some Plasma Coagulation Factors in Women with Spontaneous Miscarriage , 2015, International journal of fertility & sterility.

[6]  S. Lulaj,et al.  Prevalence and role of antithrombin III, protein C and protein S deficiencies and activated protein C resistance in Kosovo women with recurrent pregnancy loss during the first trimester of pregnancy , 2015, Journal of human reproductive sciences.

[7]  A. James Thrombosis in pregnancy and maternal outcomes. , 2015, Birth defects research. Part C, Embryo today : reviews.

[8]  R. Mattar,et al.  Thrombophilic Mutations and Polymorphisms, Alone or in Combination, and Recurrent Spontaneous Abortion , 2015, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[9]  C. Glueck,et al.  Diagnostic ramifications of ocular vascular occlusion as a first thrombotic event associated with factor V Leiden and prothrombin gene heterozygosity , 2015, Clinical ophthalmology.

[10]  M. Alfò,et al.  Maternal Thrombophilia and Adverse Pregnancy Outcome: A Case-Control Study , 2014, Acta Haematologica.

[11]  M. A. Dehkordi,et al.  Association of Deficiency of Coagulation Factors (Prs, Prc, ATIII) and FVL Positivity with Preeclampsia and/or Eclampsia in Pregnant Women , 2014, International journal of hematology-oncology and stem cell research.

[12]  V. Perez,et al.  Treatment of blepharitis: recent clinical trials. , 2014, The ocular surface.

[13]  M. Rabinowitz,et al.  Genomic Imbalance in Products of Conception: Single-Nucleotide Polymorphism Chromosomal Microarray Analysis , 2014, Obstetrics and gynecology.

[14]  D. Chang,et al.  Prospective evaluation of microinvasive glaucoma surgery with trabecular microbypass stents and prostaglandin in open‐angle glaucoma , 2014, Journal of cataract and refractive surgery.

[15]  Binbin Wang,et al.  Association between Thrombophilia Gene Polymorphisms and Preeclampsia: A Meta-Analysis , 2014, PloS one.

[16]  P. Kolar Risk Factors for Central and Branch Retinal Vein Occlusion: A Meta-Analysis of Published Clinical Data , 2014, Journal of ophthalmology.

[17]  Richard B Devereux,et al.  Risk of a thrombotic event after the 6-week postpartum period. , 2014, The New England journal of medicine.

[18]  Nilnur Eyerci,et al.  Combined genetic mutations have remarkable effect on deep venous thrombosis and/or pulmonary embolism occurence. , 2014, Gene.

[19]  D. Sullivan,et al.  Effect of azithromycin on lipid accumulation in immortalized human meibomian gland epithelial cells. , 2014, JAMA ophthalmology.

[20]  J. Gris,et al.  Comparative incidence of pregnancy outcomes in thrombophilia-positive women from the NOH-APS observational study. , 2014, Blood.

[21]  R. Lindstrom,et al.  A Phase III clinical study to evaluate the efficacy of combined azithromycin and dexamethasone in the treatment of blepharoconjunctivitis , 2013, Clinical ophthalmology.

[22]  M. Goddijn,et al.  Antithrombotic therapy for pregnancy loss. , 2013, Human reproduction update.

[23]  I. Chatziralli,et al.  BRANCH RETINAL VEIN OCCLUSION: Epidemiology, Pathogenesis, Risk Factors, Clinical Features, Diagnosis, and Complications. An Update of the Literature , 2013, Retina.

[24]  M. Rateb,et al.  Using multiple trabecular micro‐bypass stents in cataract patients to treat open‐angle glaucoma , 2012, Journal of cataract and refractive surgery.

[25]  C. Glueck,et al.  Thrombophilia and retinal vascular occlusion , 2012, Clinical ophthalmology.

[26]  Jeffrey M. Wells,et al.  Cataract surgery with trabecular micro‐bypass stent implantation in patients with mild‐to‐moderate open‐angle glaucoma and cataract: Two‐year follow‐up , 2012, Journal of cataract and refractive surgery.

[27]  A. Fadlallah,et al.  Azithromycin 1.5% ophthalmic solution: efficacy and treatment modalities in chronic blepharitis. , 2012, Arquivos brasileiros de oftalmologia.

[28]  J. García-Feijóo,et al.  Combined iStent trabecular micro-bypass stent implantation and phacoemulsification for coexistent open-angle glaucoma and cataract: a long-term study , 2012, British Journal of Ophthalmology.

[29]  Jennifer S. Harthan,et al.  Review of Azithromycin Ophthalmic 1% Solution (AzaSite®) for the Treatment of Ocular Infections , 2012, Ophthalmology and eye diseases.

[30]  A. Pleil,et al.  Changes in vision- and health-related quality of life in patients with diabetic macular edema treated with pegaptanib sodium or sham. , 2011, Investigative ophthalmology & visual science.

[31]  M. B. Sultan,et al.  A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. , 2011, Ophthalmology.

[32]  Francesco Bandello,et al.  The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. , 2011, Ophthalmology.

[33]  T. Shokeir,et al.  Determinants of fertility and reproductive success after hysteroscopic septoplasty for women with unexplained primary infertility: a prospective analysis of 88 cases. , 2011, European journal of obstetrics, gynecology, and reproductive biology.

[34]  Y. Duh,et al.  Randomized evaluation of the trabecular micro-bypass stent with phacoemulsification in patients with glaucoma and cataract. , 2011, Ophthalmology.

[35]  Dominick L Opitz,et al.  Efficacy of azithromycin 1% ophthalmic solution for treatment of ocular surface disease from posterior blepharitis , 2011, Clinical & experimental optometry.

[36]  Paul P. Lee,et al.  Glaucoma medication adherence: room for improvement in both performance and measurement. , 2011, Archives of ophthalmology.

[37]  H. Kolb,et al.  The global diabetes epidemic as a consequence of lifestyle-induced low-grade inflammation , 2010, Diabetologia.

[38]  L. Dušek,et al.  Initial Visual Acuity Is an Important Prognostic Factor in Patients with Branch Retinal Vein Occlusion , 2010, Ophthalmic Research.

[39]  I. Verdenik,et al.  Septate, subseptate and arcuate uterus decrease pregnancy and live birth rates in IVF/ICSI. , 2010, Reproductive biomedicine online.

[40]  K. Bremme,et al.  Factor V Leiden mutation and pregnancy-related complications. , 2010, American journal of obstetrics and gynecology.

[41]  R. K. Murthy,et al.  Fundus Autofluorescence and Spectral Domain Optical Coherence Tomography in Early Detection of Plaquenil Maculopathy , 2010, European journal of ophthalmology.

[42]  J. Luchs Azithromycin in DuraSite® for the treatment of blepharitis , 2010, Clinical ophthalmology.

[43]  M. Wallenstein,et al.  Inherited thrombophilia polymorphisms and pregnancy outcomes in nulliparous women. , 2010, Obstetrics and gynecology.

[44]  Lloyd Paul Aiello,et al.  Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema , 2010, Ophthalmology.

[45]  T. Peto,et al.  A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. , 2010, Ophthalmology.

[46]  Dongseok Choi,et al.  Selective thinning of the perifoveal inner retina as an early sign of hydroxychloroquine retinal toxicity , 2010, Eye.

[47]  G. Barillari,et al.  Retinal vein occlusion: evaluation of “classic” and “emerging” risk factors and treatment , 2010, Journal of Thrombosis and Thrombolysis.

[48]  G. Querques,et al.  Pegaptanib Sodium versus Pegaptanib Sodium Combined with Macular Laser Photocoagulation or Laser Alone for Diabetic Macular Edema , 2010, Journal of ophthalmology.

[49]  A. Schachat,et al.  A review of clinical trials of anti-VEGF agents for diabetic retinopathy , 2010, Graefe's Archive for Clinical and Experimental Ophthalmology.

[50]  B. Sibai,et al.  Prothrombin Gene G20210A Mutation and Obstetric Complications , 2010, Obstetrics and gynecology.

[51]  Dennis P. Han,et al.  Spectral-domain optical coherence tomography and adaptive optics may detect hydroxychloroquine retinal toxicity before symptomatic vision loss. , 2009, Transactions of the American Ophthalmological Society.

[52]  Jennifer I. Lim,et al.  Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study. , 2009, Ophthalmology.

[53]  C. Crean,et al.  Ocular surface distribution and pharmacokinetics of a novel ophthalmic 1% azithromycin formulation. , 2009, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[54]  Omer Rafaeli,et al.  PREFERENTIAL HYPERACUITY PERIMETRY TO DETECT HYDROXYCHLOROQUINE RETINAL TOXICITY , 2009, Retina.

[55]  L. Pasquale,et al.  Lifestyle, Nutrition, and Glaucoma , 2009, Journal of glaucoma.

[56]  J. Chartrand,et al.  Three-month, randomized, parallel-group comparison of brimonidine–timolol versus dorzolamide–timolol fixed-combination therapy* , 2009, Current medical research and opinion.

[57]  L. Cobellis,et al.  Hysteroscopic resection of the septum improves the pregnancy rate of women with unexplained infertility: a prospective controlled trial. , 2009, Fertility and sterility.

[58]  G. Fishman,et al.  Effects of chronic exposure to hydroxychloroquine or chloroquine on inner retinal structures , 2010, Eye.

[59]  J. García-Feijóo,et al.  Coexistent Primary Open-Angle Glaucoma and Cataract: Interim Analysis of a Trabecular Micro-Bypass Stent and Concurrent Cataract Surgery , 2009, European journal of ophthalmology.

[60]  C. Glueck,et al.  Ocular Vascular Thrombotic Events: A Diagnostic Window to Familial Thrombophilia (Compound Factor V Leiden and Prothrombin Gene Heterozygosity) and Thrombosis , 2009, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[61]  E. Davidov,et al.  Diabetic retinopathy and health-related quality of life , 2009, Graefe's Archive for Clinical and Experimental Ophthalmology.

[62]  T. Wong,et al.  Retinal vein occlusion: an approach to diagnosis, systemic risk factors and management , 2008, Internal medicine journal.

[63]  Ronald Klein,et al.  The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. , 2008, Ophthalmology.

[64]  C. Baudouin Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma , 2008, Acta ophthalmologica.

[65]  K. Digre,et al.  A NOVEL METHOD FOR SCREENING THE MULTIFOCAL ELECTRORETONOGRAM IN PATIENTS USING HYDROXYCHLOROQUINE , 2008, Retina.

[66]  C. Glueck,et al.  A Likelihood Model That Accounts for Censoring Due to Fetal Loss Can Accurately Test the Effects of Maternal and Fetal Genotype on the Probability of Miscarriage , 2008, Human Heredity.

[67]  T. Olsen,et al.  Hydroxychloroquine retinopathy screening , 2008, British Journal of Ophthalmology.

[68]  C. Dubray,et al.  Tear Concentrations of Azithromycin following Topical Administration of a Single Dose of Azithromycin 0.5%, 1.0%, and 1.5% Eyedrops (T1225) in Healthy Volunteers , 2008, European journal of ophthalmology.

[69]  J. Luchs Efficacy of topical azithromycin ophthalmic solution 1% in the treatment of posterior blepharitis , 2008, Advances in therapy.

[70]  F. Grignolo,et al.  The effects of dorzolamide 2% and dorzolamide/timolol fixed combination on retinal and optic nerve head blood flow in primary open-angle glaucoma patients , 2008, Eye.

[71]  Robert N Weinreb,et al.  Prevalence of Ocular Surface Disease in Glaucoma Patients , 2008, Journal of glaucoma.

[72]  J. García-Feijóo,et al.  Coexistent primary open-angle glaucoma and cataract: Preliminary analysis of treatment by cataract surgery and the iStent trabecular micro-bypass stent , 2008, Advances in therapy.

[73]  B. Kruft,et al.  Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines. , 2008, Ophthalmology.

[74]  J. Schouten,et al.  Side effects of commonly used glaucoma medications: comparison of tolerability, chance of discontinuation, and patient satisfaction , 2008, Graefe's Archive for Clinical and Experimental Ophthalmology.

[75]  K. Golnik,et al.  Ocular Vascular Thrombotic Events: Central Retinal Vein and Central Retinal Artery Occlusions , 2008, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[76]  Antonio Martínez,et al.  Effects of dorzolamide 2% added to timolol maleate 0.5% on intraocular pressure, retrobulbar blood flow, and the progression of visual field damage in patients with primary open-angle glaucoma: a single-center, 4-year, open-label study. , 2008, Clinical therapeutics.

[77]  Tin Aung,et al.  Prevalence and risk factors for diabetic retinopathy: the Singapore Malay Eye Study. , 2008, Ophthalmology.

[78]  K. Langová,et al.  [Disturbances of the plasma coagulation defects in retinal venous occlusions]. , 2008, Ceska a slovenska oftalmologie : casopis Ceske oftalmologicke spolecnosti a Slovenske oftalmologicke spolecnosti.

[79]  M. Margaglione,et al.  Antithrombotic prophylaxis during pregnancy in women with deficiency of natural anticoagulants , 2008, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[80]  C. Glueck,et al.  Heritable Thrombophilia-Hypofibrinolysis and Osteonecrosis of the Femoral Head , 2008, Clinical orthopaedics and related research.

[81]  C. Glueck,et al.  Factor V Leiden mutation: a treatable etiology for sporadic and recurrent pregnancy loss. , 2008, Fertility and sterility.

[82]  P. Elena,et al.  Ocular Pharmacokinetic Study Following Single and Multiple Azithromycin Administrations in Pigmented Rabbits , 2008, Current eye research.

[83]  R. Tehrani,et al.  Ocular Toxicity of Hydroxychloroquine , 2008, Seminars in ophthalmology.

[84]  I. Greer,et al.  The GOAL study: a prospective examination of the impact of factor V Leiden and ABO(H) blood groups on haemorrhagic and thrombotic pregnancy outcomes , 2007, British journal of haematology.

[85]  A. Robin,et al.  Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. , 2007, American journal of ophthalmology.

[86]  T. Reinhard,et al.  [Chronic blepharitis. Pathogenesis, clinical features, and therapy]. , 2007, Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft.

[87]  J. L. Green,et al.  Vision-related quality of life in patients with diabetic macular oedema , 2007, British Journal of Ophthalmology.

[88]  M. Batterbury,et al.  Use of eyedrops in glaucoma: how can we help to reduce non-compliance? , 2007, Acta ophthalmologica Scandinavica.

[89]  A. Girach,et al.  Diagnosed diabetic retinopathy in France, Italy, Spain, and the United Kingdom. , 2007, Primary care diabetes.

[90]  Maciej Wojtkowski,et al.  High-speed ultra-high-resolution optical coherence tomography findings in hydroxychloroquine retinopathy. , 2007, Archives of ophthalmology.

[91]  T. Zeyen,et al.  Ocular Symptoms and Signs with Preserved and Preservative-Free Glaucoma Medications , 2007, European journal of ophthalmology.

[92]  J. S. Lyons,et al.  Detection of early hydroxychloroquine retinal toxicity enhanced by ring ratio analysis of multifocal electroretinography. , 2007, American journal of ophthalmology.

[93]  V. Oriana,et al.  Role of Hyperhomocystinemia in Retinal Vascular Occlusive Disease , 2007, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[94]  Anmar M. A. Rahman,et al.  Early paracentral visual field loss in patients taking hydroxychloroquine. , 2006, Archives of ophthalmology.

[95]  M. Sherwood,et al.  Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. , 2006, Archives of ophthalmology.

[96]  U. Kellner,et al.  Fundus autofluorescence and mfERG for early detection of retinal alterations in patients using chloroquine/hydroxychloroquine. , 2006, Investigative ophthalmology & visual science.

[97]  A. Robin,et al.  Adjunctive glaucoma therapy use associated with travoprost, bimatoprost, and latanoprost , 2006, Current medical research and opinion.

[98]  B. Sibai,et al.  The relationship of the factor V Leiden mutation and pregnancy outcomes for mother and fetus. , 2006, Obstetrics and gynecology.

[99]  P. Scanlon,et al.  Reported symptoms and quality‐of‐life impacts in patients having laser treatment for sight‐threatening diabetic retinopathy , 2006, Diabetic medicine : a journal of the British Diabetic Association.

[100]  W. Steinmann,et al.  Timolol/dorzolamide combination therapy as initial treatment for intraocular pressure over 30 mm Hg. , 2005, Journal of glaucoma.

[101]  M. Marmor The dilemma of hydroxychloroquine screening: new information from the multifocal ERG. , 2005, American journal of ophthalmology.

[102]  T. Lai,et al.  Multifocal electroretinographic changes in patients receiving hydroxychloroquine therapy. , 2005, American journal of ophthalmology.

[103]  C. Glueck,et al.  The factor V Leiden mutation, high factor VIII, and high plasminogen activator inhibitor activity: etiologies for sporadic miscarriage. , 2005, Metabolism: clinical and experimental.

[104]  B. Brenner,et al.  COMMENTARY: Thrombophilia and pregnancy loss in first intended pregnancy , 2005, Journal of thrombosis and haemostasis : JTH.

[105]  Manju Patel,et al.  A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. , 2005, Ophthalmology.

[106]  F. Adatia,et al.  Chronic open-angle glaucoma. Review for primary care physicians. , 2005, Canadian family physician Medecin de famille canadien.

[107]  R. Schiffman,et al.  Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension. , 2005, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[108]  K. Golnik,et al.  Amaurosis Fugax: Associations with Heritable Thrombophilia , 2005, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[109]  C. Lines,et al.  Efficacy of the dorzolamide/timolol fixed combination versus latanoprost in the treatment of ocular hypertension or glaucoma: combined analysis of pooled data from two large randomized observer and patient-masked studies. , 2005, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[110]  Wei Liu,et al.  The impact of diabetic retinopathy on health-related quality of life. , 2005, Current opinion in ophthalmology.

[111]  J. Cruysberg,et al.  Retinal vein occlusion: A form of venous thrombosis or a complication of atherosclerosis? , 2005, Thrombosis and Haemostasis.

[112]  A. Robin,et al.  Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? , 2005, Ophthalmology.

[113]  A. G. Lee Hydroxychloroquine screening , 2005, British Journal of Ophthalmology.

[114]  S. Resnikoff,et al.  Global data on visual impairment in the year 2002. , 2004, Bulletin of the World Health Organization.

[115]  N. Goldenberg,et al.  Pregnancy Loss, Polycystic Ovary Syndrome, Thrombophilia, Hypofibrinolysis, Enoxaparin, Metformin , 2004, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[116]  T. Zimmerman,et al.  Switching from latanoprost to fixed-combination latanoprost-timolol: a 21-day, randomized, double-masked, active-control study in patients with glaucoma and ocular hypertension. , 2004, Clinical therapeutics.

[117]  B. Francis,et al.  Comparing the fixed combination dorzolamide–timolol (Cosopt®) to concomitant administration of 2% dorzolamide (Trusopt®) and 0·5% timolol – a randomized controlled trial and a replacement study , 2004, Journal of clinical pharmacy and therapeutics.

[118]  Richard G Weleber,et al.  Multifocal electroretinographic evaluation of long-term hydroxychloroquine users. , 2004, Archives of ophthalmology.

[119]  David A. Lee,et al.  Comparison of the Safety and Efficacy of Dorzolamide 2% and Brimonidine 0.2% in Patients with Glaucoma or Ocular Hypertension , 2004, Journal of glaucoma.

[120]  M. Sherwood,et al.  Is Addition of a Third or Fourth Antiglaucoma Medication Effective? , 2004, Journal of glaucoma.

[121]  T. Realini,et al.  Fixed combinations of topical glaucoma medications , 2004, Current opinion in ophthalmology.

[122]  N. Goldenberg,et al.  Associations of Thrombophilia, Hypofibrinolysis, and Retinal Vein Occlusion , 2004, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[123]  N. Goldenberg,et al.  Nonarteritic anterior ischemic optic neuropathy: associations with homozygosity for the C677T methylenetetrahydrofolate reductase mutation. , 2004, The Journal of laboratory and clinical medicine.

[124]  C. Lines,et al.  Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT) versus 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials. , 2004, Acta ophthalmologica Scandinavica.

[125]  A. Coleman,et al.  Effect of laser photocoagulation treatment for diabetic macular oedema on patient's vision-related quality of life , 2004, Current eye research.

[126]  N. Orzalesi,et al.  Replacing maximum-tolerated medications with latanoprost versus adding latanoprost to maximum-tolerated medications: a two-center randomized prospective trial. , 2003, Journal of glaucoma.

[127]  Anders Heijl,et al.  Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. , 2003, Archives of ophthalmology.

[128]  Petros P Sfikakis,et al.  The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. , 2003, Ophthalmology.

[129]  M. Cahill,et al.  Meta-analysis of plasma homocysteine, serum folate, serum vitamin B(12), and thermolabile MTHFR genotype as risk factors for retinal vascular occlusive disease. , 2003, American journal of ophthalmology.

[130]  R. Behki,et al.  Canadian perspectives in glaucoma management: setting target intraocular pressure range. , 2003, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[131]  S. Kahn,et al.  Thrombophilic disorders and fetal loss: a meta-analysis , 2003, The Lancet.

[132]  V. Rasch Cigarette, alcohol, and caffeine consumption: risk factors for spontaneous abortion , 2003, Acta obstetricia et gynecologica Scandinavica.

[133]  D. Wald,et al.  Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis , 2002, BMJ : British Medical Journal.

[134]  N. Pfeiffer A comparison of the fixed combination of latanoprost and timolol with its individual components , 2002, Graefe's Archive for Clinical and Experimental Ophthalmology.

[135]  M. C. Leske,et al.  Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. , 2002, Archives of ophthalmology.

[136]  R. Marcucci,et al.  Retinal vein thrombosis: risk factors, pathogenesis and therapeutic approach , 2002, Pathophysiology of Haemostasis and Thrombosis.

[137]  E. Higginbotham,et al.  Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial. , 2002, Archives of ophthalmology.

[138]  R. Carr,et al.  Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. , 2002, Ophthalmology.

[139]  E. E. Hartmann,et al.  The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. , 2002, Archives of ophthalmology.

[140]  C. Baudouin,et al.  Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication , 2002, The British journal of ophthalmology.

[141]  F. Parmeggiani,et al.  Recurrent central retinal vein occlusion in a young thrombophilic patient with factor V Leiden mutation. , 2002, European journal of ophthalmology.

[142]  H. Deutschmann,et al.  Hyperhomocyst(e)inemia and MTHFR C677T genotypes in patients with central retinal vein occlusion , 2002, Graefe's Archive for Clinical and Experimental Ophthalmology.

[143]  W. Dietz,et al.  Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. , 2002, JAMA.

[144]  G. Yılmaz,et al.  Retinal vein Occlusion and Factor V Leiden and Prothrombin 20210 G:A Mutations , 2001, European journal of ophthalmology.

[145]  G. Koren,et al.  Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases , 2001, The Lancet.

[146]  W. Fu,et al.  Macrolides: structures and microbial targets. , 2001, International journal of antimicrobial agents.

[147]  B. Eifrig,et al.  [Thrombophilia factors as inducers of retinal vascular occlusion]. , 2001, Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft.

[148]  U. Seligsohn,et al.  Genetic susceptibility to venous thrombosis. , 2001, The New England journal of medicine.

[149]  A. Bruce,et al.  The conjunctival epithelium in dry eye subtypes: Effect of preserved and non-preserved topical treatments , 2001, Current eye research.

[150]  M. B. Shields,et al.  A comparison of dorzolamide-timolol combination versus the concomitant drugs. , 2000, American journal of ophthalmology.

[151]  B. Prum,et al.  The advanced glaucoma intervention study (AGIS): 7. the relationship between control of intraocular pressure and visual field deterioration , 2000 .

[152]  R. Klein,et al.  Prevalence of and risk factors for dry eye syndrome. , 2000, Archives of ophthalmology.

[153]  C. Glueck,et al.  Polycystic ovary syndrome, infertility, familial thrombophilia, familial hypofibrinolysis, recurrent loss of in vitro fertilized embryos, and miscarriage. , 2000, Fertility and sterility.

[154]  J. Larsson Central retinal artery occlusion in a patient homozygous for factor V Leiden. , 2000, American journal of ophthalmology.

[155]  R. Gross,et al.  Incidence of Brimonidine Allergy in Patients Previously Allergic to Apraclonidine , 2000, Journal of glaucoma.

[156]  I. Kimura,et al.  Clinical Ophthalmology , 2000, The British journal of ophthalmology.

[157]  M. Cahill,et al.  Raised plasma homocysteine as a risk factor for retinal vascular occlusive disease , 2000, The British journal of ophthalmology.

[158]  F. Demirci,et al.  Prevalence of factor V Leiden in patients with retinal vein occlusion. , 1999, Acta ophthalmologica Scandinavica.

[159]  E. Frenkel,et al.  Antiphospholipid-Thrombosis Syndromes , 1999, Pathophysiology of Haemostasis and Thrombosis.

[160]  J. Larsson,et al.  Activated protein C resistance and anticoagulant proteins in young adults with central retinal vein occlusion. , 1999, Acta ophthalmologica Scandinavica.

[161]  W. C. Stewart,et al.  Efficacy and safety of timolol solution once daily vs timolol gel added to latanoprost. , 1999, American journal of ophthalmology.

[162]  J. Larsson,et al.  The prothrombin gene G20210A mutation and the platelet glycoprotein IIIa polymorphism PlA2 in patients with central retinal vein occlusion. , 1999, Thrombosis research.

[163]  G. Hankey,et al.  Homocysteine and vascular disease , 1999, The Lancet.

[164]  K. Maršál,et al.  Activated Protein C Resistance (FV:Q506) and Pregnancy , 1999, Thrombosis and Haemostasis.

[165]  Jones Ocular toxicity and hydroxychloroquine: guidelines for screening , 1999, The British journal of dermatology.

[166]  T. Liesegang Conjunctival changes associated with glaucoma therapy: implications for the external disease consultant and the treatment of glaucoma. , 1998, Cornea.

[167]  E. Snyder,et al.  A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Dorzolamide-Timolol Combination Study Group. , 1998, Ophthalmology.

[168]  D. Gieser,et al.  A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide-Timolol Study Group. , 1998, Ophthalmology.

[169]  R. Ritch,et al.  The Glaucoma Symptom Scale. A brief index of glaucoma-specific symptoms. , 1998, Archives of ophthalmology.

[170]  N. Newman,et al.  Retinal vein occlusion and transient monocular visual loss associated with hyperhomocystinemia. , 1997, American journal of ophthalmology.

[171]  Gerald. D. Levy,et al.  Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice. , 1997, Arthritis and rheumatism.

[172]  G. Ricci,et al.  Coagulation and fibrinolysis changes in normal pregnancy. Increased levels of procoagulants and reduced levels of inhibitors during pregnancy induce a hypercoagulable state, combined with a reactive fibrinolysis. , 1997, European journal of obstetrics, gynecology, and reproductive biology.

[173]  T. Tanbo,et al.  [Recurrent spontaneous abortions]. , 1997, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

[174]  P. D. de Jong,et al.  Increased expression of angiogenic growth factors in age-related maculopathy , 1997, The British journal of ophthalmology.

[175]  P. Reitsma,et al.  A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. , 1996, Blood.

[176]  F. Rosendaal,et al.  Increased fetal loss in women with heritable thrombophilia , 1996, The Lancet.

[177]  G. Duncker,et al.  Chloroquine-induced lipidosis in the rat retina: functional and morphological changes after withdrawal of the drug , 1996, Graefe's Archive for Clinical and Experimental Ophthalmology.

[178]  T. Williamson,et al.  Blood viscosity, coagulation, and activated protein C resistance in central retinal vein occlusion: a population controlled study. , 1996, The British journal of ophthalmology.

[179]  J. Larsson,et al.  Activated protein C resistance in young adults with central retinal vein occlusion. , 1996, The British journal of ophthalmology.

[180]  L. Aiello,et al.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. , 1994, The New England journal of medicine.

[181]  F. Rosendaal,et al.  Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study , 1993, The Lancet.

[182]  A. Sommer,et al.  Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey. , 1991, Archives of ophthalmology.

[183]  A. Andersson,et al.  Effects of long‐term chloroquine exposure on the phospholipid metabolism in retina and pigment epithelium of the mouse , 1990, Acta ophthalmologica.

[184]  A. Miller,et al.  Risk factors for spontaneous abortion and its recurrence. , 1988, American journal of epidemiology.

[185]  S. Ryan,et al.  Long-term course of chloroquine retinopathy after cessation of medication. , 1979, American journal of ophthalmology.

[186]  O. Koller [Thrombosis and pregnancy]. , 1971, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

[187]  R. Dryden CENTRAL RETINAL VEIN OCCLUSIONS AND CHRONIC SIMPLE GLAUCOMA. , 1965, Archives of ophthalmology.

[188]  C. Duan,et al.  Thrombophilia Markers in Patients with Recurrent Early Miscarriage. , 2015, Clinical laboratory.

[189]  M. Andres,et al.  [Pregnancy outcome and thrombophilia of women with recurrent fetal death]. , 2014, Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia.

[190]  S. Natarajan,et al.  Combined CRVO with CRAO in a patient with protein C deficiency. , 2014, Retinal cases & brief reports.

[191]  G. La Torre,et al.  Efficacy and safety of the intravitreal treatment of diabetic macular edema with pegaptanib: a 12-month follow-up. , 2013, La Clinica terapeutica.

[192]  Y. Farag,et al.  Diabesity: an overview of a rising epidemic. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[193]  K. Langová,et al.  The role of thrombophilia in patients with retinal vein occlusion and no systemic risk factors. , 2010, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[194]  D. Schust,et al.  Recurrent pregnancy loss: etiology, diagnosis, and therapy. , 2009, Reviews in obstetrics & gynecology.

[195]  N. Goldenberg,et al.  Enoxaparin-metformin and enoxaparin alone may safely reduce pregnancy loss. , 2009, Translational research : the journal of laboratory and clinical medicine.

[196]  R. Olson,et al.  Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of glaucoma in the adult eye. , 2009, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[197]  Ami A. Shah,et al.  Use of azithromycin ophthalmic solution in the treatment of chronic mixed anterior blepharitis. , 2008, Annals of ophthalmology.

[198]  A. Konstas,et al.  Comparison of the 24-hour intraocular pressure-lowering effects of latanoprost and dorzolamide/timolol fixed combination after 2 and 6 months of treatment. , 2008, Ophthalmology.

[199]  D. Hollander,et al.  Brimonidine purite 0.1% versus brinzolamide 1% as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension. , 2008, Current medical research and opinion.

[200]  M. Prins,et al.  Intraocular pressure-lowering effect of adding dorzolamide or latanoprost to timolol: a meta-analysis of randomized clinical trials. , 2007, Ophthalmology.

[201]  I. Goldberg,et al.  Topical Dorzolamide 2%/Timolol 0.5% Ophthalmic Solution A Review of its Use in the Treatment of Glaucoma and Ocular Hypertension , 2006 .

[202]  N. Bressler,et al.  Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. , 2006, Ophthalmology.

[203]  J. Rouland,et al.  The Economic Burden of Glaucoma and Ocular Hypertension , 2005, Drugs & aging.

[204]  G. Schwartz,et al.  Persistency with latanoprost or timolol in primary open-angle glaucoma suspects. , 2004, American journal of ophthalmology.

[205]  S. Berliner,et al.  Retinal artery occlusion in a patient with factor V Leiden and prothrombin G20210A mutations. , 2002, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[206]  C. Fegan,et al.  Central retinal vein occlusion and thrombophilia , 2002, Eye.

[207]  H. Yamashita,et al.  Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. , 2002, American journal of ophthalmology.

[208]  J. Gamel Retinal vascular occlusion and deficiencies in the protein C pathway. , 2000, American journal of ophthalmology.

[209]  D. Fitzgerald,et al.  Prospective evaluation of the risk conferred by factor V Leiden and thermolabile methylenetetrahydrofolate reductase polymorphisms in pregnancy. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[210]  M. Easterbrook Detection and prevention of maculopathy associated with antimalarial agents. , 1999, International ophthalmology clinics.

[211]  F. Demirci,et al.  Ocular involvement in primary antiphospholipid syndrome. Ocular involvement in primary APS. , 1998, International ophthalmology.

[212]  S. Owens,et al.  Comparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence study. International Clinical Equivalence Study Group. , 1998, The British journal of ophthalmology.

[213]  G. Duncker,et al.  Chloroquine-induced lipidosis in the rat retina: a functional and morphological study. , 1995, Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde.

[214]  J. Folkman,et al.  Increased Vascular Endothelial Growth Factor Levels in the Vitreous of Eyes With Proliferative Diabetic Retinopathy , 1995 .